Indeed, blockade of free fatty acid release by tumor cells or free fatty acid uptake by Treg cells (via anti-CD36 antibody treatment or Treg cell-specific deletion of CD36) decreases intratumoral Treg cell accumulation and reverses tumor resistance to anti-PD-1 treatment [93, 95]. Here, PDCD1 is linked to neoplasm.